Ocular Therapeutix (OCUL) Assets Average (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Assets Average of $701.9 million for Q2 2026, up 63.76% year-over-year from $428.6 million in Q2 2025, and down 8.88% on a QoQ basis from $770.3 million in Q1 2026.
Ocular Therapeutix (OCUL) Assets Average (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Assets Average for 13 years, with the latest figure at $701.9 million in Q2 2026.
- Assets Average for Q2 2026 came in at $701.9 million, up 63.76% year-over-year; the trailing twelve-month figure through Jun 2026 was $701.9 million (up 63.76% YoY), and the FY2025 annual result was $633.0 million, up 78.31% from the prior year.
- Assets Average eased to $701.9 million in Q2 2026, from $770.3 million in the prior quarter.
- Over five years, Assets Average peaked at $770.3 million in Q1 2026 and troughed at $125.6 million in Q2 2023.
- A 5-year average of $365.9 million and a median of $412.1 million in 2024 frame the typical range for Assets Average.
- The widest annual swing landed in 2023, when Assets Average sank 30.38%; it then surged 320.51% in 2024.
- A 5-year view of Assets Average shows it stood at $153.9 million in 2022, then jumped by 34.62% to $207.2 million in 2023, then jumped by 128.81% to $474.2 million in 2024, then climbed by 28.54% to $609.5 million in 2025, then grew by 15.17% to $701.9 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $701.9 million in Q2 2026, $770.3 million in Q1 2026, and $609.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 701.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 701.92 Mn |
| Mar 31, 2026 | 770.29 Mn |
| Dec 31, 2025 | 609.47 Mn |
| Sep 30, 2025 | 431.11 Mn |
| Jun 30, 2025 | 428.63 Mn |
| Mar 31, 2025 | 431.93 Mn |
| Dec 31, 2024 | 474.15 Mn |
| Sep 30, 2024 | 503.73 Mn |
| Jun 30, 2024 | 528.02 Mn |
| Mar 31, 2024 | 395.50 Mn |
| Dec 31, 2023 | 207.22 Mn |
| Sep 30, 2023 | 142.47 Mn |
| Jun 30, 2023 | 125.57 Mn |
| Mar 31, 2023 | 138.93 Mn |
| Dec 31, 2022 | 153.93 Mn |
| Sep 30, 2022 | 165.83 Mn |
| Jun 30, 2022 | 180.35 Mn |
| Mar 31, 2022 | 196.25 Mn |
| Dec 31, 2021 | 211.31 Mn |
| Sep 30, 2021 | 224.22 Mn |